Immobilized human PD-1 at 0.5 μg/ml (50 μL/well) can bind to Nivolumab with a linear range of 0.305 ng/ml-5 μg/ml.
Product Details
Product Details
Product Specification
Host | Human |
Antigen | PD-1 |
Synonyms | Programmed cell death protein 1, Protein PD-1, hPD-1, CD279, PDCD1 |
Accession | Q15116 |
Clone Number | S-SC016 |
Antibody Type | Recombinant mAb |
Isotype | IgG4,k |
Application | Blocking of PD-1/PD-L signaling Functional assays |
Purification | Protein A |
Concentration | 2 mg/ml |
Endotoxin | <1EU/mg |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4, containing no preservative |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
application | dilution | species |
ELISA | 0.305-5000 ng/ml |
Background
Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.
Picture
Picture
ELISA
